Kaplan–Meier survival curves for overall survival stratified by BM LGALS3 mRNA expression in the original cohort. In 211 non-M3 AML patients who received conventional intensive chemotherapy, patients with higher LGALS3 expression had shorter OS (A). The survival curves stratified by LGALS3 mRNA expression into four quartiles showing patients in the highest (4th) quartile of LGALS3 expression had the worst prognosis, whereas those in the lowest (1st) quartile had the best prognosis (B). In the subgroup of 109 patients with CN-AML, patients with higher LGALS3 expression had shorter OS (C). The median value of BM LGALS3 expression in the original cohort of 280 patients was used as the cutoff point to define lower- and higher-expression groups (A and C).